Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550589 · ClinicalTrials.gov registry record · Phase 2
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00550589 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 33 participants.
The verdict
NCT00550589, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming cancer. PURPOSE: This phase II trial is studying the side effects and how well topical cidofovir works in treating HIV-infected patients with high-grade squamous intraepithelial lesions of the skin near the anus.
Interventions
- GENETIC gene expression analysis
- PROCEDURE biopsy
- GENETIC polymerase chain reaction
- DRUG cidofovir
- GENETIC DNA methylation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550589
The ClinicalTrials.gov registry entry for NCT00550589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00550589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550589 about?
NCT00550589 is a clinical study titled "Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus". RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming cancer. PURPOSE: This phase II trial is studying the side effects and how ...
What is the current status of trial NCT00550589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2007-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00550589?
The interventions under investigation include: gene expression analysis (GENETIC), biopsy (PROCEDURE), polymerase chain reaction (GENETIC), cidofovir (DRUG), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00550589?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.